This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million.

The Motley Fool • Dec 9, 2025

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.

Zacks Investment Research • Dec 4, 2025

Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment

Pharvaris stock surged Wednesday — and KalVista reversed higher — on promising test results for an HAE treatment.

Investors Business Daily • Dec 3, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris N.V. (NASDAQ: PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.

Benzinga • Dec 3, 2025

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Seeking Alpha • Dec 3, 2025

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p

GlobeNewsWire • Dec 3, 2025

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now

Increased Pharvaris stake by 500,000 shares, with a net position value change of $67.83 million Transaction represented 0.3% of General Atlantic, L.P.'s 13F reportable assets under management (AUM) Post-trade holding: 8,031,252 shares valued at $200.38 million The Pharvaris position now accounts for 6.0% of fund AUM, which places it outside the fund's top five holdings

The Motley Fool • Dec 3, 2025

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement).

Seeking Alpha • Nov 23, 2025

Why Bain Capital Is Selling Shares of This Biotech Stock Now

Sold 122,106 shares of Pharvaris N.V, reducing position value by $21.23 million Post-trade holding: 3,181,275 shares valued at $79.37 million Position now accounts for 5.27% of AUM, ranking as the fund's 4th-largest holding

The Motley Fool • Nov 18, 2025

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Data presented at recent medical congresses, including final outcomes from the completed open-label extension phase of the Phase 2 CHAPTER-1 study, reinforce the potential of deucrictibant to differentiate through its efficacy and safety profile Strong financial position with cash and cash equivalents of €329 million as of September 30, 2025 ZUG, Switzerland, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We remain on track to report data from the pivotal Phase 3 trial, RAPIDe-3, in the fourth quarter of 2025,” said Berndt Modig, Chief Executive Officer of Pharvaris.

GlobeNewsWire • Nov 12, 2025